

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A01N 1/00, A61M 1/14, 37/00 A61L 33/00, C08J 7/04</p>	<p>A1</p>	<p>(11) International Publication Number: WO 91/15952 (43) International Publication Date: 31 October 1991 (31.10.91)</p>
<p>(21) International Application Number: PCT/US91/02415 (22) International Filing Date: 9 April 1991 (09.04.91) (30) Priority data: 509,063 12 April 1990 (12.04.90) US (71) Applicant: CARDIOPULMONICS, INC. [US/US]; 5060 West Amelia Earhart Drive, Salt Lake City, UT 84116 (US). (72) Inventors: WINTERS, Suzanne ; 637 2nd Avenue, Salt Lake City, UT 84103 (US). SOLEN, Kenneth, A. ; 536 East 500 South, Orem, UT 84058 (US). SANDERS, Clifton, G. ; 633 East 200 South, Apt. #1, Salt Lake City, UT 84102 (US). MORTENSEN, J., D. ; 10600 Dimple Dell Road, Sandy, UT 84092 (US). BERRY, Gaylord ; 1896 Vine Street, Salt Lake City, UT 84121 (US).</p>	<p>(74) Agents: NYDEGGER, Rick, D. et al.; Workman, Nydegger & Jensen, 1000 Eagle Gate Tower, 60 East South Temple, Salt Lake City, UT 84111 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i></p>	
<p>(54) Title: GAS PERMEABLE THROMBO-RESISTANT COATINGS AND METHODS OF MANUFACTURE</p> <p>(57) Abstract</p> <p>The present invention is directed to thrombo-resistant coatings for use with gas permeable biomedical devices and implants. The coatings include a <u>siloxane surface</u> onto which a plurality of amine functional groups have been bonded. Covalently bonded to the amine functional groups are a plurality of poly(ethylene oxide) chains, such that a single poly(ethylene oxide) chain is bonded to a single amine functional group. A quantity of at least one bioactive molecule designed to counteract a specific blood-material incompatibility reaction is covalently bonded to the poly(ethylene oxide) chains, such that a single bioactive molecule is coupled to a single polyethylene oxide chain. The methods of manufacturing the present invention include preparing a material having a siloxane surface onto which a plurality of amine functional groups have been bonded. This is preferably achieved by plasma etching with ammonia gas. The amine-containing siloxane surface is reacted with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine groups on the siloxane surface. The material is then reacted with a solution of at least one bioactive molecule which counteracts a blood-material incompatibility reaction, such that a single bioactive molecule is coupled to a single poly(ethylene oxide) chain. The resulting siloxane surface is capable of resisting blood-material incompatibility reactions while maintaining high gas permeability.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

1

**GAS PERMEABLE THROMBO-RESISTANT
COATINGS AND METHODS OF MANUFACTURE**

BACKGROUND

5

1. The Field of the Invention

The invention relates to thrombo-resistant compositions for coating gas permeable polymers and to the methods of manufacturing such coatings so that the resulting product remains gas permeable and thrombo-resistant. More particularly, the present invention immobilizes at least one bioactive molecule, such as heparin, to a gas permeable siloxane surface in order to combat at least one blood-material incompatibility reaction.

15

2. The Prior Art

Over the years, a large number of medical devices have been developed which contact blood. The degree of blood contact varies with the device and its use in the body. For instance, catheters may briefly contact the blood, while implants, such as heart valves and vascular grafts, may contact blood for a number of years. Regardless of the device, blood contact with foreign materials initiates the process of thrombosis, which may be followed by formation of thromboemboli.

25

Adsorption of proteins is one of the first events to occur when blood contacts a foreign surface. The compositions and conformation of adsorbed proteins influence subsequent cellular responses such as platelet adhesion, aggregation, secretion, complement activation, and ultimately, the formation of cross-linked fibrin and thrombus. Thrombus formation is an obvious and potentially debilitating response to foreign material in contact with blood.

35

1

The initial protein layer at the blood-material interface is subject to denaturation, replacement, and further reaction with blood components. During this phase of protein adsorption, adsorbed fibrinogen is converted to fibrin. Fibrin formation is accompanied by the adherence of platelets and possibly leucocytes. The platelets become activated and release the contents of their granules. This activates other platelets, thereby resulting in platelet aggregation.

10

A thrombus eventually forms from entrapment of erythrocytes (red blood cells) and other blood constituents in the growing fibrin network. Thrombus growth can eventually lead to partial or even total blockage of the vascular channel and/or interference with the function of the device unless the thrombus is sheared off or otherwise released from the foreign surface as an embolus. Unfortunately, such emboli can be as dangerous as blockage of the vascular channel since emboli can travel through the bloodstream, lodge in vital organs, and cause infarction of tissues. Infarction of the heart, lungs, or brain, for example, can be fatal. Therefore, the degree to which the foreign material inhibits thrombus formation, embolization, and protein denaturation is a determinant of its usefulness as a biomaterial.

20

25

In the past, the thrombogenicity of biomedical implants has been treated by the administration of systemic anticoagulants such as heparin and warfarin. However, long-term anticoagulation therapy is not advisable due to the risk of hazardous side effects. Moreover, overdose of anticoagulants may cause lethal side reactions, such as visceral or cerebral bleeding. For these reasons, there have been extensive efforts to develop materials which can be used in biomedical devices or implants which can contact

30

35

1 blood with minimal or no systemic anticoagulation therapy
being necessary to avoid thrombus formation.

Many studies have attempted to produce a nonthrom-
5 bogenic blood-contacting surface through immobilization of
biologically active molecules onto the surface. Such
bioactive molecules counteract various blood-material
incompatibility reactions.

Surface modification of polymeric materials offers the
10 advantage of optimizing the chemical nature of the
blood/polymer interface while allowing a choice of the
substrate to be based upon the necessary mechanical
properties of the blood-contacting device.

The methods used to immobilize bioactive molecules
15 onto blood-contacting surfaces fall into four general
groups: physical adsorption, physical entrapment,
electrostatic attraction, and covalent binding.

Surfaces incorporating bioactive molecules by physical
adsorption or entrapment beneath the blood-contacting
20 surface exhibit a significant degree of thrombo-resistance.
However, depletion of the bioactive molecules into the
blood environment causes the surface to rapidly lose its
thrombo-resistant character. Entrained molecules diffuse
to the surface which, along with physically adsorbed
25 bioactives, are then "leached" from the surface into the
blood plasma by mechanical and chemical mechanisms.

Similarly, electrostatically or ionically bound
molecules are subject to partitioning and ion exchange
between the blood-contacting surface and the electrolyte-
30 rich plasma resulting in depletion. Covalently bound
bioactive molecules resist depletion sufficiently to offer
a potentially "long term" thrombo-resistant effect.

Numerous studies of covalent attachment of different
biomolecules are available. These studies generally
35 involve the covalent attachment of a single bioactive

1 molecule, usually heparin, designed to counteract one
aspect of the blood-material incompatibility reactions.
Most studies have focused on covalently binding heparin to
5 a blood-contacting surface. Heparin is the most effective
anticoagulant in clinical use today. It is a highly
sulfonated mucopolysaccharide containing a number of
charged functional groups. Heparin enhances the
inactivation of thrombin by antithrombin III, thereby
10 inhibiting the conversion of fibrinogen to fibrin.

Most prior attempts to covalently bind heparin to a
blood-contacting surface have severely decreased the
activity of heparin. For example, heparin coupled to a
blood-contacting surface through one of its carboxyl groups
15 may lose up to 90% of its activity. Other systems,
claiming covalent attachment of heparin, are actually
heparin covalently bound to a coupling molecule which is
subsequently ionically bound to the substrate.

Additional problems are encountered when the blood-
20 contacting surface must also be gas permeable. Siloxane
polymers are of particular interest in blood gas exchange
devices because siloxane polymers not only possess certain
inherent thrombo-resistant properties, but siloxane
polymers also are gas permeable. However, siloxane
25 polymers are relatively inert and pose a significant
obstacle in modifying the surface in order to become more
thrombo-resistant.

From the foregoing, it will be appreciated that what
is needed in the art are thrombo-resistant compositions and
30 methods which do not inhibit the gas permeability of the
blood-contacting surface. Especially needed are methods
for conferring thrombo-resistance to siloxane polymers.

It would be another important advancement in the art
to provide gas permeable thrombo-resistant compositions and
35 methods in which a bioactive molecule, such as heparin, is

1 covalently bound to the gas permeable blood-contacting surface, thereby eliminating elution of the bioactive molecule into the blood plasma.

5 It would be a further advancement in the art to provide gas permeable thrombo-resistant compositions and methods in which the bioactive molecules retain their activity after immobilization on the gas permeable blood-contacting surface.

10 Such gas permeable thrombo-resistant compositions and methods are disclosed and claimed herein.

BRIEF SUMMARY OF THE INVENTION

15 The present invention is directed to gas permeable thrombo-resistant coatings for use with gas permeable biomedical devices and implants. A quantity of at least one bioactive molecule selected to counteract a specific blood-material incompatibility reaction is preferably immobilized onto the gas permeable polymeric surface of the device which contacts the blood.

20 Siloxane is the presently preferred substrate surface (that is, to which bioactive molecules are bonded), because the substrate itself is initially relatively thrombo-resistant. Moreover, siloxane is gas permeable, thereby enabling the coatings of the present invention to be used in a variety of gas permeable applications.

25 In order to overcome the inertness of the siloxane surface, functional groups, preferably amine groups, are introduced onto the siloxane surface. Amine functionalities are preferably introduced onto the siloxane surface by plasma etching with ammonia gas. It is also possible to introduce amine functionalities onto the siloxane surface by addition of ammonia gas during plasma polymerization of a siloxane monomer.

1

In one currently preferred embodiment of the present invention, the amine functional groups on the siloxane surface are reacted with an aqueous solution of poly(ethylene oxide) bis(glycidyl ether). Other poly(ethylene oxide) (hereinafter referred to as "PEO") derivatives which may be successfully used within the scope of the present invention are aqueous solutions of poly(ethylene oxide) bis(2-amino-1,4-benzoquinone). After such reaction occurs, the siloxane surface contains PEO chains coupled to the amine groups. The PEO spacer chains are presently preferred because the PEO tends to minimize protein adsorption.

The unbound terminal end groups on the PEO chains readily react with the amine groups found in many bioactive molecules. The desired bioactive molecule is covalently bonded to one end of the PEO chains in a reaction similar to the reaction which covalently bonds the other end of the PEO chain to the gas permeable siloxane surface.

Since the desired bioactive molecule is spaced away from the siloxane surface at one end of a long PEO chain, the bioactive molecule possesses an activity approaching the activity of the bioactive molecule in solution. Because of this mobility of the bioactive molecule near the blood-contacting surface of the polymer, the effectiveness of the bioactive molecule is substantially greater than the same bioactive molecule bound directly to the blood-contacting surface. At the same time, the serious risks associated with systemic anticoagulation therapy are avoided.

Typical bioactive molecules which may be immobilized on a gas permeable siloxane surface within the scope of the present invention include: heparin, ticlopidine, iloprost, prostaglandin E₁ (PGE₁), streptokinase, urokinase, and plasmin.

35

1 Heparin inhibits the blood incompatibility reaction
resulting in clotting and thromboemboli formation by
interacting with antithrombin III and thrombin to inhibit
5 the conversion of fibrinogen to fibrin.

Ticlopidine, prostaglandin E₁, and synthetic
prostaglandin analogues, such as iloprost, inhibit the
activation of platelets either by minimizing aggregation or
inhibiting activation and the release of the intracellular
10 platelet activators. Each drug has a slightly different
mode of action. Urokinase, streptokinase, and plasmin are
serine proteases which lyse formed protein deposits and
networks, which while not inhibiting thrombus formation,
breakdown any formed fibrin.

15 The present invention is unique because it enables a
gas permeable siloxane surface to be coated with one or
more bioactive molecules covalently bound thereto.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 The present invention provides a thrombo-resistant
coating for use with a gas permeable blood-contacting
surface of a medical device or implant. While it will
immediately be appreciated that the present invention is
applicable to a wide variety of other medical devices and
25 implants, the coatings of the present invention are
particularly suited for use with blood gas exchange
devices. In any blood gas exchange device it is critical
to both minimize thrombus and emboli formation, while at
the same time preserving the gas exchange capabilities of
30 the device.

Accordingly, for purposes of illustration, the
coatings of the present invention are discussed with
respect to one such blood gas exchange device (as described
in the above-identified U.S. Patent No. 4,850,958 entitled
35 "Apparatus and Method for In Vivo Extrapulmonary Blood Gas

1 Exchange"); however, it is not intended that the invention
is to be construed as limited for use on only such a
device.

5

A. Bioactive Molecules

To minimize the thrombo-resistant properties of any
blood-contacting surface within the scope of the present
invention, a quantity of at least one bioactive molecule
10 which counteracts a specific blood-material incompatibility
reaction is immobilized or linked to the blood-contacting
surface.

The bioactive molecule is selected to inhibit blood
material incompatibility reactions such as: coagulation
15 and thrombus formation; platelet destruction, injury,
entrapment, aggregation, and activation; complement
activation; lysis of fibrin; and protein adsorption.
Table I provides a summary of the various bioactive
molecules which may be used within the scope of the present
20 invention to combat blood-material incompatibility
reactions.

25

30

35

1

TABLE I

5	BLOOD INCOMPATIBILITY REACTION	BIOACTIVE SUBSTANCE	TYPE OF BIOACTIVITY
	Extrinsic coagulation pathway activation	Heparin	Interruption of the conversion of fibrinogen to fibrin
10	Platelet destruction and injury, adhesion, and aggregation analogues release,	Prostaglandin E ₁ and synthetic prostaglandin	Inhibits platelet shape change, platelet factor secretion and aggregation
15		Ticlopidine	Protects platelets and inhibits platelet aggregation
20	Fibrin Formation	Plasmin Urokinase Streptokinase	Lyses fibrin Converts plasmin- ogen to plasmin, general proteolytic enzyme.
25		TPA	Activates plasminogen
30	Complement activation	FUT-175	Inhibits C1 _s , C1 _i , thrombin, and kallikrein

30

35

1 Any of the various bioactive molecules immobilized
onto the surface gives the blood-contacting surface a
thrombo-resistant coating. The term "thrombo-resistant" is
5 generally used herein to generically represent the action
of inhibiting any of the blood incompatibility reactions
discussed above. Thus, despite substantial surface contact
with blood, thrombus formation on the surface of the
medical device or implant (e.g., a blood gas exchange
10 device) is inhibited or counteracted according to the
compositions and methods within the scope of the present
invention.

It will be appreciated that Table I lists only a few
of the bioactive substances which inhibit the identified
15 blood-material incompatibility reactions and that other
bioactive substances may be used in accordance with the
present invention to make a surface thrombo-resistant. As
is discussed hereinafter, another important feature of the
bioactive molecules used in the present invention is the
20 availability of a primary amine (or other suitable
functional groups) to react with the unbound functional end
group on a molecule attached to the substrate surface.

B. Blood Gas Exchange Device

25 The blood gas exchange devices to which the present
invention is particularly applicable include both sheet
membrane and tubular membrane oxygenators. Numerous
oxygenators of these types are well known in the prior art.

For purposes of illustration, one blood gas exchange
30 device to which the present invention is applicable
includes a dual lumen tube containing two coaxial lumens.
The outer lumen opens into an airtight proximal chamber to
which the proximal ends of a plurality of elongated gas
permeable tubes are attached. The inner lumen extends past
35 the outer lumen and passes among the gas permeable tubes.

1 Both the inner lumen and the distal ends of gas permeable tubes open into an airtight distal chamber.

5 The device is inserted into the patient's venae cavae through an incision made in either the common femoral vein or the internal jugular vein. The gas permeable tubes are crimped in order to maintain the tubes in a spaced relation one from another so that the blood may flow freely between and around the tubes, thereby enhancing the blood surface
10 contact with the gas permeable tubes.

One of either the inner or outer lumens is connected to a source of oxygen-rich gas. The other lumen is connected to an exhaust tube or other means for allowing the gas to flow out of the device. The oxygen-rich gas
15 flows through the gas permeable tubes. As venous blood flows around the gas permeable tubes, oxygen passes from the tubes into the blood, thereby causing blood oxygenation, and carbon dioxide passes from the blood into the tubes and out of the body.

20 One of the primary goals of a blood gas exchange device (whether or not it has the specific configuration discussed above) is to maximize the gas transfer surface area in contact with the blood. Unfortunately, as the surface area of a foreign device in contact with blood
25 increases, the risk of triggering a host of blood-material incompatibility reactions also increases.

Traditionally, as mentioned above, when a large quantity of blood contacts a foreign surface, systemic anticoagulants or thrombolytic agents are administered.
30 Extreme care must be taken when administering any anticoagulants or thrombolytic agents to avoid the potential risk of serious hemorrhage both internally and externally. Thus, it is important that the blood-contacting surface of a blood gas exchange device is both
35 gas permeable and thrombo-resistant. For these reasons,

1 when the present invention is used with a blood gas
exchange device, the blood-contacting surface is preferably
constructed of a thin siloxane polymer.

5

C. Obtaining a Gas Permeable Siloxane Surface

In the blood-gas exchange device of the present
invention, microporous hollow fibers coated with a plasma-
polymerized siloxane are used as the substrate. The term
10 "plasma" refers to a thermodynamically non-equilibrium
state. The energized electrons in the field can interact
with the organic monomer or gases which produce mainly free
radicals and ions. Any object in the field is subject to
a negative charge of its surface. Ions and free radicals
15 will impact the object's surface and under certain
conditions a "plasma" thin film will form on the surface.

Two opposing processes occur simultaneously during
plasma discharge. In general, it can be said that the
generation of free radicals in the vapor phase lead to the
20 formation of thin films. However, at high power of field
strength, ions are generally responsible for ablation or
"etching" of the surface. Generally at very low gas or
monomer flow rates there is little polymer deposition and
the deposition rate decreases with increasing discharge
25 power. At higher flow rates, the deposition increases
(linearly), but reaches a maximum with increasing discharge
power and then ablation becomes more predominant.

The amount and relative position of polymer deposition
is influenced by at least three geometric factors:
30 (1) location of the electrode and distribution of charge;
(2) monomer flow; and (3) substrate position within the
reactor relative to the glow region. In the case of hollow
fibers which are pulled continuously through the plasma
chamber, the influence of the substrate position is

35

1 averaged over the length of the fibers. This is the
currently preferred polymer deposition arrangement.

5 The population of energetic species that contribute to
the direct formation of plasma polymer is not directly or
uniquely related to the power input into the system. The
intensity of a non-polymer forming plasma (i.e., plasma
etching) is dependent on the combined factors of pressure
and discharge power as well as on other factors of the
10 discharge system such as distance between electrodes,
surface area of electrodes, and total volume of the
reactor.

Various parameters have been used to describe the
energy input of plasma polymerization such as current
15 density, current and voltage, or wattage. These parameters
may have varying degrees of applicability to an inductively
or capacitively coupled Radio Frequency ("RF") discharge
system. However, such parameters are insufficient to
describe the change in total volume of plasma and the
20 plasma polymerization that takes place in the volume,
although certain correlations can be found between the
deposition rates and these parameters, but only for a given
set of experimental conditions.

An important feature of the present invention,
25 particularly for use with a blood oxygenator, is the
creation of a smooth, continuous (pin-hole free) thin
coating (less than 1 micron thick) over the pores of the
hollow fiber. The thickness of this coating can be
determined gravimetrically, and the continuity of the
30 coating can be determined by the permeability. These
factors, along with the chemical composition (i.e., carbon,
silicone, oxygen, nitrogen percentages, determined by ESCA)
are some of the values which change as plasma parameters
are modified.

1

The chemical composition of the plasma coating affects the gas permeability. For example, as the cross-link density increases, the permeability decreases. Factors which affect the cross-link density include: pressure, power, flow rate, and position within the reactor. Gas permeability is also influenced by the plasma deposition thickness and the completeness of coverage of the pores.

5 The pressure, temperature, gas flow rates, exposure time, power, and other parameters in a plasma process are highly interdependent and highly dependent upon the size and geometry of the plasma chamber. The power per unit area is an important parameter in reproducibly controlling the chemical structure of the resulting polymer. However, since plasma polymerization and etching procedures and techniques are well known, a detailed discussion of each of the process parameters is not provided herein.

15 Plasma may be generated by a number of methods including combustion, flames, electric discharge, controlled nuclear reactions and shocks. The most obvious and commonly used is the electric discharge. Radio frequency ("RF") or microwave discharge are mainly used for polymerization reactions. For the commercial RF generators, the frequency is dictated by the Federal Communications Commission and is set at 13.56 MHz.

25 One currently preferred plasma machine used for the deposition of the siloxane membrane consists of a central bell jar with four peripheral vacuum chambers attached via glow zone pyrex tubing approximately 24 inches long. The RF discharge is coupled capacitively through two pair of copper electrodes on each arm. Therefore, each arm has two (2) glow zones.

30 The microporous hollow fiber substrate is pulled through from feed spools in the peripheral chambers through a system of pulleys such that the fiber passes through the

35

1 glow tubes more than once is taken up on spools in the
central bell jar. The vacuum, RF power, monomer flow rate,
and fiber speed are all computer controlled.

5 The currently preferred operating parameters are to
expose the polypropylene microporous hollow fiber to a
siloxane monomer having a mass flow rate of about 12
 μ moles/second/arm at an absolute pressure of about 65
mtorr. The fiber is pulled through each arm at a speed of
10 about 3.2 cm/sec. A radio frequency of 13.56 MHz at about
17 watts/arm is applied to the fiber.

The above conditions produce a cross-linked siloxane
membrane on the polypropylene microporous hollow fiber on
the order of about 0.5 to about 1.0 microns in thickness.
15 When 1,3-divinyldimethyltetramethyl disiloxane is the siloxane
monomer, the membrane has been found to have an oxygen
permeability ranging from about 0.37×10^{-4} cm³/sec·cm²·cm Hg
to about 3.4×10^{-4} cm³/sec·cm²·cm Hg and a carbon dioxide
permeability ranging from 0.8×10^{-4} cm³/sec·cm²·cm Hg to
20 about 5.0×10^{-4} cm³/sec·cm²·cm Hg. The permselectivity
(ratio of permeabilities) of the membrane is in the range
from about 2.5 to about 4.0.

When tetramethyl disiloxane is the siloxane monomer,
the membrane has been found to have an oxygen permeability
25 ranging from about 0.9×10^{-4} cm³/sec·cm²·cm Hg to about 1.9
 $\times 10^{-4}$ cm³/sec·cm²·cm Hg and a carbon dioxide permeability
ranging from about 3.5×10^{-4} cm³/sec·cm²·cm Hg to about 5.2
 $\times 10^{-4}$ cm³/sec·cm²·cm Hg.

It will be appreciated that there are other methods
30 for producing suitable siloxane coated hollow fibers.
Nevertheless, the foregoing discussion is included to
provide one skilled in the art with an understanding of one
preferred method of producing suitable siloxane coated
hollow fibers and typical parameters of such fibers.

1

D. Linking the Bioactive Molecules onto the Blood
Contacting Surface

5 For purposes of illustration, reference will be made
to "linking" or "immobilizing" bioactive molecules on the
blood-contacting substrate surface of a blood gas exchange
device. It will be readily appreciated that the principles
and teachings of the present invention are generally
applicable to most other medical devices and implants which
10 contact blood and have a problem with thrombus and emboli
formation.

Moreover, it will be appreciated that the term
"immobilized" is being used in the sense that the bioactive
molecules are covalently linked or "tethered" to a specific
15 portion of the polymer substrate vis-a-vis free floating in
the blood. Therefore, even though the bioactive molecules
may not be directly attached to the blood-contacting
surface (as discussed in greater detail below), the
bioactive molecules are closely associated to the surface
20 through a linkage such that the blood components contact
the bioactive molecules as they come proximate to the
blood-contacting surface.

Most of the bioactive molecules described above are
capable of being immobilized to the blood-contacting
25 surface of the blood gas exchange device through PEO
coupling molecules. PEO is the preferred coupling
molecule, because PEO itself functions to minimize protein
adsorption. This property of PEO is believed to be due in
part to PEO's unique hydrophobic and hydrophilic
30 characteristics.

Because the blood-contacting surface of the blood-gas
exchange device is preferably constructed of siloxane, the
inherent inertness of the siloxane polymer minimizes
thrombus formation. However, this same inherent inertness

35

1 of the siloxane significantly complicates the method of
immobilizing the bioactive molecules to the surface.

To overcome the inertness of the siloxane, functional
5 groups are introduced on the siloxane surface. These
functional groups provide distinct and predictable sites
for reaction with PEO. The PEO chains are then coupled to
the blood-contacting surface through the functional groups.
In the currently preferred embodiment of the present
10 invention, amine groups are introduced onto the siloxane
surface.

1. Introduction of Amine Groups by Plasma Etching

One proposed method for introducing amine groups on
15 the siloxane surface within the scope of the present
invention involves plasma etching with ammonia gas. In the
blood-gas exchange device of the present invention,
microporous hollow fibers coated with a plasma-polymerized
siloxane, described above, are used as the substrate.
20 These fibers are subjected to additional plasma exposure in
the presence of ammonia gas.

One plasma chamber used for plasma etching within the
scope of the present invention has a volume of about 20,000
cm³ and capacitively coupled plate-type electrodes. The
25 siloxane plasma-coated fibers, having a surface area of
about 2,100 cm², are exposed to ammonia having a flow rate
in the range of from about 100 micromoles per second to
about 300 micromoles per second, at an absolute pressure in
the range from about 100 millitorr to about 200 mtorr. The
30 exposure time ranges from about thirty (30) seconds to
about fifteen minutes. The currently preferred exposure
time is in the range from about 10 minutes to about 15
minutes. A radio frequency of 13.56 MHz in the range from
about 20 watts to about 250 watts generates sufficient

1 energy to break the molecular bonds of both the ammonia gas and the siloxane surface.

It will be appreciated by those skilled in the art that in a differently configured plasma chamber, the ammonia flow rate, power, chamber pressure, and exposure time may be outside the ranges of that set forth for the embodiment discussed above. Nevertheless, current experimental testing suggests that the power should relate to the monomer or gas flow rate such that W/FM is in the range from 30-50 megajoules/Kg, where W is the discharge power in joules per second, F is the mass flow rate in moles per second, and M is the molecular weight of a gas (g/mole). However, this value (W/FM) does not take into consideration the power density which is determined by the volume of the plasma chamber. Because the minimum wattage necessary for the plasma polymer of a given monomer differs significantly from that of another monomer at a given pressure, it becomes immediately obvious that W , wattage per square centimeter, or current density alone is not sufficient to describe the conditions of plasma polymerization. Hence, the flow rate, power, and pressure may well be outside of the ranges given.

In light of these stoichiometric relationships, those skilled in the art can readily determine relationships between the flow rate, the pressure, and the exposure times of the siloxane surface to the ammonia.

Ammonia derivatives, existing as free radicals and ions react with each other and with the siloxane surface, thereby introducing amine functionalities onto the siloxane surface. Analysis by electron spectroscopy for chemical analysis ("ESCA") establishes that nitrogen in the form of amine functionalities can be introduced onto the surface on the order of from about three (3) to about seven (7) total atomic percent. ESCA measurements of about three total

1 atomic percent have been found to result in a satisfactory end product. Other polymers not as inert as siloxanes are capable of incorporating much higher amounts of nitrogen.

5 It should be noted that ESCA analyzes only the top 50-100 angstroms of a surface. Analysis of bulk structure below the sampling depth is not possible with ESCA. In addition, the atomic percent reported by ESCA is for the entire volume analyzed (*i.e.*, the top 50-100 angstroms).
10 Thus, 3% nitrogen detected does not correspond with 3% of the surface atoms being nitrogen. Because of the bulk contribution to the ESCA signal, the actual percent nitrogen atoms on the surface would be significantly greater than 3%.

15 Nevertheless, ESCA does establish the existence of significant amounts of nitrogen at or near the surface. Moreover, analysis of percent nitrogen provides a valuable approximation for the number of free amines on the surface. The quantity of amines bound to the surface directly
20 affects the coupling efficiency of the PEO or bioactive molecules. Thus, the more amine groups, the more PEO coupling sites.

From the foregoing, it will be appreciated that the parameters associated with ammonia etching are highly
25 interdependent and dependent upon the specific plasma chamber. The following examples illustrate this interdependence. One skilled in the art would appreciate that the parameters described in the following examples can be modified when using a different sized plasma chamber.

30

EXAMPLE 1

Amine groups were introduced onto the surface of siloxane-coated hollow fibers within the scope of the present invention by plasma etching in the presence of
35 ammonia. A plurality of microporous hollow fibers

1 incorporated into a fully formed intravenous extrapulmonary
blood oxygenator were used as the substrate. The fibers
were coated with plasma-polymerized siloxane.

5 The siloxane coated hollow fibers forming the
oxygenator were subjected to plasma exposure in the
presence of ammonia gas. The entire oxygenator was placed
in a plasma chamber. The dimensions of the plasma chamber
10 were fifteen inches long, twelve inches wide and five
inches high. The electrodes were in the form of two
parallel plates capacitively coupled in the chamber. The
oxygenator was subjected to plasma exposure by introducing
ammonia gas into the plasma chamber at the flow rate of 190
15 micromoles per second at 170 mtorr absolute pressure. The
hollow fibers were exposed to 180 watts at a radio
frequency of 13.56 MHz for fifteen minutes.

According to ESCA analysis, nitrogen in the form of
amine functionalities was introduced onto the surface on
the order of three total atomic percent. As discussed
20 hereinafter, this amount of nitrogen provides sufficient
amine reaction sites for attachment of the PEO and the
multifunctional bioactive molecules.

EXAMPLE 2

25 Amine groups were introduced onto the surface of a
siloxane-coated hollow fibers according to the procedure of
Example 1, except that fiber sheets, instead of a fully
formed oxygenator, are placed in racks between the
electrodes. Utilizing the procedures of Example 2,
30 nitrogen in the form of amine functionalities was
introduced onto the surface as analyzed by ESCA on the
order of six total atomic percent.

Additional examples of introducing amine
functionalities by ammonia etching are presented in


1 copen ding patent application Serial No. 07/215,014,
 Examples 1-8 which are incorporated by reference.


5 2. Introduction of Amine Groups by Plasma
Polymerization

Another method for introducing the amine
 functionalities onto the blood-contacting surface of the
 siloxane polymer is to introduce the amine groups during
 10 the siloxane polymerization itself. This process, known as
 plasma polymerization or glow discharge polymerization, is
 achieved by introducing a siloxane monomer vapor and
 ammonia gas simultaneously in the presence of the plasma.
 The same type of tubular chamber used for plasma deposition
 15 of siloxane may be used for plasma polymerization of
 siloxane in the presence of ammonia gas.

3. Amine Functionalities on the Siloxane Surface

Both ammonia etching and plasma polymerization with
 20 ammonia result in amine incorporation into or onto the
 siloxane polymer. ESCA analysis of the resulting surface
 demonstrates the existence of Si-H bonds, C-N bonds, amine
 (NH₂) groups, and carbonyl (C=O) groups. In addition, the
 surface likely includes reactive radicals (e.g., •CH₂ and
 25 •NH). While the exact surface structure resulting from
 these reaction processes is not known, the resulting
 surface structure is believed to be a combination of a
 number of possible bond and group configurations including:





5 R may be H or OH.

The degree of cross-linking (*i.e.*, the number of bonds formed from methyl radicals on adjacent polymer chains reacting together to form an ethylene unit between chains) is totally dependent upon the reaction parameters. Any polymerization performed using plasma results in a "plasma polymer." The structure of a plasma polymer is significantly different from those resulting from other known polymerization mechanisms; these plasma polymers are by nature "ill-defined."

It will be appreciated that an important aspect of the present invention is the incorporation of amine functionalities (which are available for reaction with PEO) on the blood-contacting surface. Hence, other plasma reaction processes which introduce amine functionalities onto the surface are useful as a part of the present invention.

For example, another possible process for introducing amine functionalities on the blood-contacting surface would be to coat the surface with siloxane monomer in the plasma, and then introduce another polymerizable gas which contains amine groups. One potentially suitable amine-containing polymerizable gas is allylamine.

In addition, depending on the type of siloxane monomer used to form the siloxane surface, nitrogen gas is a suitable alternative to ammonia gas in both the plasma etching and plasma polymerization processes described above. Nitrogen gas initially introduces both amine groups and nitrogen radicals onto the siloxane surface, but upon exposure to water vapor, the nitrogen radicals quickly

1 quench to form amine groups. Because nitrogen is less
expensive than ammonia, the use of nitrogen gas can
significantly reduce the costs associated with the plasma
5 process described above.

Although the foregoing discussion has focused on the
incorporation of amine groups onto the siloxane surface, it
will be appreciated that the principles within the scope of
the present invention may be readily adapted to incorporate
10 other reactive functional groups onto the siloxane surface.

Thus, an important aspect of the invention is the
incorporation of any reactive functional group such as
hydroxyl, carbonyl, or carboxylic groups onto the siloxane
surface. These functional groups would provide a chemical
15 "handle" on the otherwise inert siloxane surface to which
PEO and bioactive molecules may be bound.

The surfaces which emerge from the plasma in any of
the processes discussed above are highly reactive. While
exact molecular analysis is difficult, the surfaces likely
20 contain some radicals which are available for reacting with
almost any species containing double bonds which come into
contact with the siloxane surface.

4. Reaction of Amine Functionalities with PEO.

25 Immediately upon removal from the plasma, the surfaces
of the hollow fibers may be reacted with the terminal end
groups of unbranched PEO. The PEO functions as an extended
flexible spacer to tether bioactive molecules away from,
but in close proximity to, the siloxane surface, thereby
30 avoiding problems of steric hindrance of adjacent bioactive
molecules which may then be coupled to the siloxane
surface. Moreover, as discussed above, the PEO itself also
assists in minimizing protein adsorption on the siloxane
surface.

1

A PEO solution is prepared by dissolving poly(ethylene oxide) bis(glycidyl ether) (commonly known as "PEO diglycidyl ether," or "polyoxyethylene diglycidyl ether") in water. The PEO must be in excess to minimize "looping" of the PEO by both reactive ends coupling to the amine groups on the surface. Typical PEO concentrations are in the range from about 5% to about 36%, and preferably about 5% to about 10%.

5

10

Poly(ethylene oxide) bis(glycidyl ether) of any molecular weight may be used. However, for maximum protein resistance, the range should be from about 1500 to about 6000 and preferably in the range from about 3000 to about 4000. It has been found that PEO within this molecular weight range minimizes the protein adsorption and maximizes repulsion of platelets and other formed elements from the surface. There is a balance between chain length and stability as well. Longer chains are more susceptible to chain scission. Shorter PEO chains are less flexible, which reduces their protein-resistant properties.

15

20

25

30

Many terminal reactive groups on PEO may be used depending upon the functionality on the siloxane to which coupling is desired. In addition to epoxide terminated PEO, other suitable terminal groups include 2-(aminoalkyl)-1,4-benzoquinone, bis-(aminediacetic acid), bis-(aminediacetic acid ethyl ester), bis-(aminediacetic acid methyl ester), bis-(amineacetic acid), bis-(3,5-dioxomorpholine), bis-succinyl-monoamide(monophthalimide), and bis-phosphate(pyrophosphate). In any event, only those PEO chains with two or more reactive functional groups would be available for coupling to a surface and to a bioactive molecule.


35

In the case of epoxide-terminated PEO, the percent epoxide within the PEO varies depending upon the manufacturer and can vary from about 10% to greater than

1 75% epoxide. The percentage epoxide directly affects the
coupling efficiency. Therefore, if 100% of all PEO chains
contain terminal epoxide groups, theoretically all could
5 bind not only to the surface but also be available for
binding bioactive molecules.

The plasma-coated fibers of the blood gas exchange
device are allowed to sit in the PEO solution, with
agitation, for about twelve hours. It has been found that
10 the amount of PEO coupling (as determined by ESCA) does not
significantly increase after fifteen (15) hours. In
addition, increasing the concentration of PEO (to about 36
weight percent in the solvent) does not significantly
increase the amount of coupling over the same time
15 interval. The temperature of the PEO solution is
preferably maintained at ambient temperature, in the range
from about 20°C to about 30°C.

After removal from the PEO solution, the coated hollow
fibers are rinsed with purified water to remove any unbound
20 PEO. The epoxide groups located at the terminal ends of
the PEO chains have reacted with the amine groups located
on the siloxane surface as shown below:



30 Upon analysis by ESCA, the surface typically contains ether
carbon of the carbon 1s spectrum in the range from about
20% to about 50% of the total carbon signal. These carbon

1 atoms on the surface are attributed to PEO attachment to the siloxane surface of the siloxane-coated substrate.

Due to the large excess of PEO used and reaction
5 conditions, only one end of the PEO chain is bound to an amine group on the siloxane surface. As a result, each PEO chain contains an unreacted epoxide group at its unbound end. The epoxide effectively reacts with the electron-rich amine nitrogen because epoxide is a highly strained three-
10 member ring. It also contains an electron depleted carbon atom. The epoxide efficiency is due mainly to the strained ring.

In addition, any carbon radicals ($\cdot\text{CH}_2$) remaining on the surface following plasma polymerization would not be
15 expected to react with the epoxide groups and would continue to be reactive.

It has been found that the PEO chains may also be suitably terminated with isocyanate functionalities if done under nonaqueous conditions. Other PEO derivatives which
20 should produce suitable results are identified above.

Despite the process used to incorporate the amine functionalities onto the siloxane surface, the PEO can readily react with the amine groups to attach the PEO to the siloxane surface.

25

5. PEO Reaction With Bioactive Molecules.

According to the present invention, the unbound end of the PEO is reacted with a quantity of at least one bioactive molecule to covalently bond the bioactive
30 molecules to the PEO which is itself bonded to the gas permeable siloxane surface. An important preferred embodiment of the present invention is to bind the bioactive molecules to the PEO linkages in order to result in a polymer surface having thrombo-resistant properties.

35

1 Such bonding of bioactive molecules to the PEO on the
siloxane surface of a blood gas exchange device occurs when
the device is placed in a solution containing the desired
5 bioactive molecule. One currently preferred bioactive
molecule solution is a 5% (wt/vol) heparin/water solution.


 The heparin solution is prepared by dissolving heparin
in 100 ml phosphate buffered saline (having a pH in the
range of from about 7.1 to about 7.5, preferably a pH of
10 about 7.4) resulting in a concentration in the range from
about 500 to about 1500 USP units per milliliter.
Preferably, the heparin concentration is about 850 USP
units per milliliter.

 The PEO/siloxane surface is preferably soaked in the
15 heparin solution for about 12 hours with agitation. The
heparin solution is maintained at ambient temperature in
the range from about 20°C to about 30°C. Upon removal from
the solution, the surface is washed with purified water,
air dried, and sterilized with ethylene oxide.


20 The heparin surface concentration of samples prepared
in this manner are found to contain approximately 0.025
 $\mu\text{g}/\text{cm}^2$ of heparin by radio isotope methods. These surfaces
are also capable of specifically binding antithrombin III
demonstrating their activity. The gas permeability of
25 formed intravenous blood oxygenator devices treated in this
way remains significantly greater during operation than
untreated microporous hollow fibers or siloxane coated
fibers without the PEO and heparin.

 It has been found that the heparin, or other bioactive
30 molecules, are coupled to the epoxide groups of the PEO
chains through any primary amines available on the
bioactive molecule. While the exact mechanism is not
known, it is theorized that the heparin, urokinase,
plasmin, and other bioactive pharmaceuticals are coupled to
35 the PEO as shown below.

1



10 "NH₂-DRUG" refers to an amine-containing bioactive molecule. The bioactive molecules are coupled to 2-(aminoalkyl)-1,4-benzoquinone-terminated PEO chains through a similar mechanism shown below.



30 Thrombogenicity tests were performed utilizing the "Acute Canine Intra-Arterial Thrombogenicity Assay" procedure described in Mortensen et al., "A Practical Screening Test for Thrombogenicity of Intraarterial Catheters -- Preliminary Report," Artificial Organs, Vol.

35

1 2, Supp., pp. 76-80, 1978, which is incorporated herein by
reference. Thrombogenicity testing results have indicated
that the heparin molecules are present and active on the
5 surface. Small bundles of treated hollow fibers were
implanted into the carotid and femoral arteries of large
dogs for a period of 30 minutes. The amount of adherent
thrombus and that expelled from the artery following
withdrawal of the bundle was weighed and compared with the
10 controls.

Siloxane coated surfaces with PEO and heparin
demonstrated an index of 0.016 while control surfaces
exhibit an index of 0.060. Statistically significant
differences were determined with 95% confidence limits.
15 Other commercially available surfaces with and without
heparin were also tested and found to produce indices
ranging from 0.002 to 0.250.

The long term efficacy of siloxane coated surfaces
with PEO and heparin covalently bound thereto as described
20 above was tested in the Chronic Ovine Intra-Venous
Thrombogenicity Assay. Briefly, this assay involves
implantation of approximately 20 cm catheter samples into
the right and left femoral and jugular veins of 70 kg sheep
through multiple venotomies. The catheters are left in
25 place for a period of 15 days with no systemic heparin
administered after surgery. The animal is permitted normal
activity for a period of 15 days after which heparin is
administered prior to sacrificing the animal. The veins
are surgically removed and opened to expose the catheter
30 lying in place. The appearance and distribution of the
thrombus present is documented photographically. The
thrombogenicity score is developed from determination of
the thickness of the clot on the catheter, the amount of
adherent clot to the vein wall, the amount of free clot in
35 the vein and the percent occlusion of the vein by thrombus.

1 In addition, the catheters are rated by gross thrombus
weight for comparison. Each catheter is tested in three
animals with a control surface. All data are normalized
5 by analysis of covariance to correct for animal to animal
variations. Commercially available catheters with and
without other heparin coatings are included in the
analyses.

The geometric mean thrombus weights ranged from 544.6
10 mg to 1754.3 mg for all catheter samples tested. Devices
having a siloxane coated surface with PEO and heparin
covalently bound thereto within the scope of the present
invention produced a mean thrombus weight of 544.6 mg,
superior to all other catheters tested. This demonstrates
15 that other commercial coatings involving ionically bound
heparin were not effective in the inhibition of thrombosis
over the 15 day testing period. The observed differences
are significant within 90% confidence limits. The amount
of thrombus formed on the commercial devices was
20 considerably greater than the amount of thrombus formed on
devices having a thrombo-resistant coating within the scope
of the present invention.

The data indicate that while some catheters tested
were heparin coated, they did not perform significantly
25 better in prevention of thrombus formation than other non-
heparinized coatings, and they did not perform as well as
devices having a siloxane coated surface with PEO and
heparin covalently bound thereto. This follows from a
theoretical argument that ionically bound heparin will
30 leach from a surface and become depleted within a very
short time. The thrombo-resistant coating within the scope
of the present invention, which covalently binds heparin to
the siloxane surface through a PEO linkage, was the only
heparinized coating catheter to maintain heparin activity
35 over the 15 day testing period.

1 Not only should the thrombo-resistant coatings within
the scope of the present invention inhibit thrombus
formation, but also maintain suitable gas permeability over
5 time. Intravenous blood oxygenator devices containing
microporous hollow fibers coated with a siloxane membrane
and treated with PEO and heparin within the scope of the
present invention were implanted in the vena cavae of
sheep. The oxygenator devices maintained suitable gas
10 transfer over a period of nineteen (19) days with less than
10% loss of efficiency.

E. Summary

15 In summary, the thrombo-resistant compositions and
methods disclosed herein are capable of counteracting
blood-material incompatibility reactions without inhibiting
the gas permeability of the blood-contacting surface. This
is accomplished by immobilizing a quantity of at least one
20 bioactive molecule which counteracts a specific blood
material incompatibility reaction to the blood-contacting
siloxane surface through individual poly(ethylene oxide)
spacer chains. Because the bioactive molecules are
tethered away from the blood-contacting surface, the
molecules avoid problems of steric hindrance and possess an
25 activity approaching the activity in solution. In
addition, the bioactive molecules are covalently bound to
the blood-contacting surface, thereby eliminating leaching
of the bioactive molecules into the blood plasma and
prolonging the effectiveness of the thrombo-resistant
30 composition.

The present invention may be embodied in other
specific forms without departing from its spirit or
essential characteristics. The described embodiments are
to be considered in all respects only as illustrative and
35 not restrictive. The scope of the invention is, therefore,

1 indicated by the appended claims rather than by the
foregoing description. All changes which come within the
meaning and range of equivalency of the claims are to be
5 embraced within their scope.

What is claimed is:

10

15

20

25

30

35

1

1. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood, the method comprising the steps of:

5

(a) obtaining a gas permeable material having a gas permeable siloxane surface onto which a plurality of amine functional groups have been bonded;

10

(b) reacting the amine functional groups on the siloxane surface with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups on the siloxane surface, thereby resulting in a product having single poly(ethylene oxide) chains which are bonded to corresponding single amine functional groups, said product being gas permeable;

15

(c) reacting the product of step (b) with at least one bioactive molecule capable of counteracting at least one blood-material incompatibility reaction such that a single bioactive molecule is correspondingly coupled to a single poly(ethylene oxide) chain, thereby resulting in a gas permeable siloxane surface to which are attached, by a poly(ethylene oxide) chain, a plurality of the at least one bioactive molecule which react with blood components which come in proximity to the siloxane surface of the gas permeable material in order to resist at least one blood-material incompatibility reaction.

20

25

30

2. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 1, wherein the step of obtaining a gas permeable material having a siloxane surface onto which a plurality of amine functional groups have been bonded comprises the steps of:

35

1

introducing ammonia gas within a plasma chamber capable of performing plasma etching;

5

exposing the ammonia gas to a radio frequency of sufficient power to create a plasma; and

exposing the siloxane surface to the ammonia plasma for sufficient time to introduce amine functional groups onto the siloxane surface.

10

3. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 2, further comprising the step of obtaining a microporous hollow fiber having a siloxane surface thereon.

15

4. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in Claim 1, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups comprises poly(ethylene oxide) bis(glycidyl ether).

20

5. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in Claim 1, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups comprises poly(ethylene oxide) 2-(aminoalkyl)-1,4-benzoquinone.

25

30

6. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 1, wherein the poly(ethylene oxide) chains have a molecular weight in the range from about 1500 to 6000.

35

1
7. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 1, wherein the product of step
5 (b) is reacted with a solution of at least one bioactive
molecule capable of resisting at least one of the following
blood-material incompatibility reactions: extrinsic
coagulation pathway activation, platelet destruction and
injury, platelet adhesion activation, platelet aggregation,
10 thrombus formation, complement activation, contact system
activation, and fibrinolytic system activation.

8. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
15 blood as defined in claim 1, wherein the product of step
(b) is reacted with heparin.

9. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
20 blood as defined in claim 1, wherein the product of step
(b) is reacted with at least one bioactive molecule
selected from the group including heparin, urokinase,
plasmin, and ticlopidine.

25 10. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 1, wherein the product of step
(b) is reacted with at least one bioactive molecule
selected from the group including heparin, urokinase, and
30 prostaglandin E₁.

11. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 1, wherein the product of step
35 (b) is reacted with at least one bioactive molecule

1 selected from the group including heparin, plasmin, and
ticlopidine.

5 12. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 1, wherein the product of step
(b) is reacted with at least one bioactive molecule
selected from the group including heparin, urokinase,
10 plasmin, prostaglandin E₁, and ticlopidine.

13. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood, the method comprising the steps of:

15 (a) obtaining a gas permeable material having a
siloxane surface;

(b) introducing ammonia gas within a plasma
chamber capable of performing plasma etching;

20 (c) exposing the ammonia gas to a radio
frequency of sufficient power to create a plasma;

(d) exposing the siloxane surface to the ammonia
plasma for sufficient time to introduce amine
functional groups onto the siloxane surface, thereby
resulting in a product having a plurality of amine
functional groups bonded onto the siloxane surface;

25 (e) reacting the product of step (d) with a
solution having a plurality of poly(ethylene oxide)
spacer chains, having the following general formula



30 wherein R₁ and R₂ are suitable functional groups
capable of reacting with the amine functional groups
on the siloxane surface; and

(f) reacting the product of step (e) with a
solution of at least one bioactive molecule capable of
35 counteracting specific blood-material incompatibility

1 reactions such that a single bioactive molecule is
correspondingly coupled to a single poly(ethylene
oxide) spacer chain, thereby resulting in a siloxane
5 surface to which are attached, by a poly(ethylene
oxide) chain, a plurality of the at least one
bioactive molecules which react with blood components
which come in proximity to the surface of the material
in order to resist at least one blood-material
10 incompatibility reaction.

14. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 13, wherein R_1 and R_2 comprise
15 glycidyl ether.

15. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 13, wherein R_1 and R_2 comprise 2-
20 (aminoalkyl)-1,4-benzoquinone.

16. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 13, wherein the product of step
25 (e) is reacted with heparin.

17. A method for producing a thrombo-resistant
coating for use on gas permeable surfaces which contact
blood as defined in claim 13, wherein the product of step
30 (e) is reacted with a plurality of at least one bioactive
molecule selected from the group including heparin,
urokinase, plasmin, and ticlopidine.

18. A method for producing a thrombo-resistant
35 coating for use on gas permeable surfaces which contact

1 blood as defined in claim 13, wherein the product of step
(e) is reacted with a plurality of at least one bioactive
molecule selected from the group including heparin,
5 urokinase, plasmin, ticlopidine, and prostaglandin E₁.

19. A thrombo-resistant composition for use on gas permeable surfaces which contact blood comprising:

10 a gas permeable material having a siloxane surface onto which a plurality of at least one bioactive molecule are covalently bonded, said at least one bioactive molecule counteracting at least one specific blood-material incompatibility reaction when the blood comes into proximity of the surface of
15 the material; and

a plurality of poly(ethylene oxide) chains covalently bonded to the bioactive molecules and covalently bonded to the siloxane surface such that a single bioactive molecule is correspondingly coupled
20 to a single poly(ethylene oxide) chain which in turn is bonded to the gas permeable siloxane surface.

20. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim
25 19, wherein the at least one bioactive molecule is capable of resisting at least one of the following blood material incompatibility reactions: extrinsic coagulation pathway activation, platelet destruction and injury, platelet adhesion, platelet aggregation, thrombus formation, and
30 complement activation.

21. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim
19, wherein the at least one bioactive molecule is heparin.

1

22. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim 19, wherein the at least one bioactive molecule is selected from the group including heparin, urokinase, plasmin, ticlopidine, and prostaglandin E₁.

10

23. A thrombo-resistant composition for use on gas permeable surfaces which contact blood, the composition being made by a process comprising the steps of:

(a) obtaining a gas permeable material having a siloxane surface onto which a plurality of amine functional groups have been bonded;

15

(b) reacting the amine functional groups on the siloxane surface with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups on the siloxane surface such that a single poly(ethylene oxide) chain is bonded to a corresponding single amine functional group; and

20

(c) reacting the product of step (b) with heparin such that a single heparin molecule is covalently bonded to a single poly(ethylene oxide) chain, thereby resulting in a siloxane surface to which are attached, by a poly(ethylene oxide) chain, a plurality of heparin molecules capable of reacting with blood components which come in proximity to the siloxane surface of the material in order to resist at least one blood-material incompatibility reactions.

25

30

24. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in Claim 23, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine

35

1 functional groups comprises poly(ethylene oxide)
bis(glycidyl ether).


5 25. A thrombo-resistant composition for use on gas
permeable surfaces which contact blood as defined in Claim
23, wherein the poly(ethylene oxide) chains terminated with
functional groups capable of reacting with the amine
functional groups comprises poly(ethylene oxide) 2-
10 (aminoalkyl)-1,4-benzoquinone.

26. A thrombo-resistant composition comprising a
plurality of compounds having the formula



15 wherein X is a siloxane surface; and wherein R_1 are R_2 are
the residue resulting from a reaction between a
poly(ethylene oxide) terminal group capable of reacting
with an amine and capable of reacting with a bioactive
molecule, respectively; and wherein Y is a bioactive
20 molecule capable of counteracting a specific blood material
incompatibility reaction.

27. A thrombo-resistant composition as defined in
claim 26, wherein R_1 is



28. A thrombo-resistant composition as defined in
claim 26, wherein Y is heparin.
30

29. A thrombo-resistant composition as defined in
claim 26, wherein Y is heparin, ticlopidine, or urokinase.

1

30. A thrombo-resistant composition as defined in claim 26, wherein Y is heparin, prostaglandin E₁, plasmin, urokinase, or tissue plasminogen activator.

5

31. A thrombo-resistant composition as defined in claim 26, wherein Y is heparin, ticlopidine, plasmin, urokinase, tissue plasminogen activator, or FUT-175.

10

32. A thrombo-resistant composition as defined in claim 26, wherein Y is capable of resisting either extrinsic coagulation pathway activation, platelet destruction and injury, platelet adhesion, platelet aggregation, thrombus formation, or complement activation.

15

33. An apparatus for effecting extrapulmonary blood gas exchange comprising:

20

a plurality of gas permeable tubes, each tube having a proximal end and a distal end, said gas permeable tubes being coated with a thrombo-resistant composition comprising a plurality of compounds having the formula



25

wherein X is a siloxane surface on a gas permeable tube; and wherein R₁ are R₂ are the residue resulting from a reaction between a poly(ethylene oxide) terminal group capable of reacting with an amine and capable of reacting with a bioactive molecule, respectively; and wherein Y is a bioactive molecule capable of counteracting at least one blood-material incompatibility reaction;

30

35

a dual lumen coaxial tube comprising an inner lumen and an outer lumen, said inner lumen extending between the proximal and distal ends of the gas permeable tubes and said outer lumen terminating

1 adjacent to the proximal ends of the gas permeable
tubes and the inner lumen terminating adjacent to the
distal ends of the gas permeable tubes, such that the
5 gas permeable tubes are in gaseous communication with
both the inner lumen and the outer lumen;

means for introducing oxygen from the inner lumen
into the distal ends of the gas permeable tubes
whereby blood in contact with the gas permeable tubes
10 receives oxygen from the gas permeable tubes and
releases carbon dioxide gas to the gas permeable
tubes; and

means for collecting carbon dioxide at the
proximal ends of the gas permeable tubes and
15 introducing said carbon dioxide into the outer lumen
for removal therethrough.

34. An apparatus for effecting extrapulmonary blood
gas exchange as defined in claim 33, wherein the at least
20 one bioactive molecule comprises heparin.

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02415

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A01N 1/00; A61M 1/14, 37/00; A61L 33/00; C08J 7/04 U.S. CL. 523/112; 422/48; 604/4, 26, 43, 49		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	523/112; 422/48; 604/4, 26, 43, 49	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	US, A, 4,349,467 (WILLIAMS ET AL) 14 SEPTEMBER 1982; See the entire document.	1-32
<u>X</u> Y	S.W. KIM ET AL, "Nonthrombogenic Bioactive Surfaces", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Volume 516, (1987) pages 116-130. See the entire document.	<u>1-32</u> 33-34
<u>X</u> Y	HOLLAHAN ET AL, "Attachment of Amino Groups to Polymer Surfaces by Radiofrequency Plasmas": JOURNAL OF APPLIED POLYMER SCIENCE VOL. 13, pages 807-816 (1969). See the entire document.	<u>1-32</u> 33-34
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
21 JUNE 1991		31 JUL 1991
International Searching Authority		Signature of Authorized Officer
ISA/US		<i>for</i> Thomas McDonald, Jr.